{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Return to MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
  • Sign In
  • Home
  • Live
  • On-Demand
  • RSS/Grand Rounds
  • Non-Accredited
  • About
  • Contact Us
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

MD Anderson workforce members:  Select "MD ANDERSON LOGIN" and enter your MD Anderson email address and password.

Guests (all other than MD Anderson workforce members): Select "GUEST LOGIN" and enter your email address and password.

MD ANDERSON LOGIN
GUEST LOGIN
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • AA
  • AAS
  • ADN
  • BA
  • BS
  • BSN
  • DDS
  • DMD
  • DMin
  • DNP
  • DO
  • DrPH
  • DVM
  • DVM,PhD
  • EdD
  • JD
  • MA
  • MBA
  • MBBS
  • MBBS,MD
  • MD
  • MD, MBA
  • MD, MPH
  • MD, PhD
  • MDiv
  • MEd
  • MHA
  • MPA
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • Other
  • PharmD
  • PharmD, PhD
  • PhD
  • PsyD
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

Enhancing Survival and Minimizing Toxicity: Leveraging New Research in HER2+ and HR+/HER2- Breast Cancers


ONLINEHER2

  • Overview
  • Faculty
  • View Content
  • Grant Supporters


Date & Location
Tuesday, November 17, 2020, 12:00 AM - Wednesday, November 17, 2021, 11:59 PM

Target Audience
Specialties - Anesthesiology, Critical Care Medicine, Developmental-Behavioral Pediatrics, Diagnostic Radiology, Emergency Medicine, Endocrinology, Diabetes and Metabolism, Epilepsy, Family Medicine, Gastroenterology, General Surgery, Geriatric Medicine, Geriatric Psychiatry, Gynecologic Oncology, Hospice and Palliative Medicine, Infectious Disease, Internal Medicine, Interventional Cardiology, Maternal-Fetal Medicine, Medical Biochemical Genetics, Medical Genetics and Genomics, Medical Microbiology Pathology, Neuroradiology, Nuclear Medicine, Ophthalmology, Pathology, Pediatric Hospital Medicine, Pediatrics, Plastic Surgery, Pulmonary Disease, Radiation Oncology, Thoracic Surgery
Professions - Nurse - RN, Physician (MD or DO)

Credits
AMA PRA Category 1 Credits™ (4.50 hours), Non-Physician Attendance (4.50 hours)

Overview
Enhancing Survival and Minimizing Toxicity: Leveraging New Research in HER2+ and HR+/HER2- Breast Cancers is a 4.50 hour internet enduring activity designed to deliver knowledge-based education regarding novel and emerging therapies as well as competency focused education to support precision medicine for breast cancer patients.

Objectives
At the conclusion of this educational activity, the participant should be able to:

  1. Describe new strategies being employed or under study to minimize toxicities in early breast cancer
  2. Explain how novel drug classes, either recently approved or nearing FDA approval, are influencing the treatment of metastatic breast cancer
  3. Discuss the mechanisms of action and key features of novel agents for breast cancer with recent FDA approval or nearing FDA approval

Accreditation
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Additional Information

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 




The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.



Supported by educational grants from AstraZeneca and Daiichi Sankyo. 

Enhancing Survival and Minimizing Toxicity: Leveraging New Research in HER2+ and HR+/HER2- Breast Cancers
Go to Site

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
 Privacy policies   

©2023 The University of Texas MD Anderson Cancer Center
Contact Us: [email protected]

See us on Facebook See us on Twitter See us on Linked In See us on Instagram